CPSE:NOVO BPharmaceuticals
Novo Nordisk Tests Wegovy Subscriptions As Obesity Drug Rivalry Intensifies
Novo Nordisk (CPSE:NOVO B) has launched a discounted multi month subscription program for obesity drug Wegovy.
The program includes both injection and pill formats and is offered through major telehealth partners.
The move follows recent FDA approval of Eli Lilly's oral weight loss drug Foundayo, which is preparing for launch.
The subscription aims to offer lower, more predictable monthly costs for self pay patients.
Novo Nordisk, best known for its diabetes and obesity treatments, now...